SIC
SAGE

SJS Investment Consulting’s Sage Therapeutics SAGE Stock Holding History

SJS Investment Consulting’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8
Closed -$150 – 1705
2024
Q1 		$150 Hold
8
– – ﹤0.01% 1526
2023
Q4 		$174 Hold
8
– – ﹤0.01% 1485
2023
Q3 		$165 Sell
8
-2
-20% -$58 ﹤0.01% 1486
2023
Q2 		$471 Buy
10
+2
+25% +$100 ﹤0.01% 1185
2023
Q1 		$336 Buy
8
+2
+33% +$86 ﹤0.01% 1261
2022
Q4 		$229 Sell
6
-3
-33% -$115 ﹤0.01% 1393
2022
Q3 		$0 Buy
+9
New +$348 ﹤0.01% 1479

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

SJS Investment Consulting's SAGE Position: Q2 2024 in Review

SJS Investment Consulting sold out of Sage Therapeutics (SAGE) in Q2 2024, closing a stake of 8 shares — an estimated $150 sold.

SJS Investment Consulting first reported a position in SAGE in Q3 2022 and held it in 7 quarters. The position peaked at $471 in Q2 2023. 195 funds tracked by Wall St. Rank hold SAGE as of Q2 2024.

  • SJS Investment Consulting reported no remaining Sage Therapeutics position as of Q2 2024 after selling out during the quarter.
  • SJS Investment Consulting sold 8 Sage Therapeutics shares in Q2 2024, an estimated $150.
  • SJS Investment Consulting first reported a position in Sage Therapeutics in Q3 2022 and held it in 7 quarters.
  • SJS Investment Consulting's Sage Therapeutics position peaked at $471 in Q2 2023.
  • 195 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2024.

Based on SJS Investment Consulting's 13F filing for Q2 2024, filed 16 Jul 2024.